SARS News and Research

RSS

Preclinical study from NIH/Moderna: Correlates of SARS-CoV-2 immunity in non-human primates

Researchers in the United States have shown that the antibody response induced by the Moderna mRNA-1273 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a correlate of immune protection against coronavirus disease 2019 (COVID-19) in non-human primates.

22 Apr 2021

Slow COVID-19 vaccine rollout in Tokyo could mean no Olympic and Paralympic Games

Researchers in Japan have warned that Tokyo's Olympic and Paralympic Games, which is set to start in July 2021, may need canceling if the rollout of vaccination to protect against coronavirus disease 2019 (COVID-19) continues at the slow pace it is now.

22 Apr 2021

New Phase 3 trial of therapeutics begins enrolling severely ill hospitalized COVID-19 patients

A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure.

22 Apr 2021

House flies can carry SARS-CoV-2 up to 24 hours after exposure, study finds

A team of researchers in the USA – at Kansas State University and Agricultural Research Service – found that house flies can acquire and harbor infectious SARS-CoV-2 for up to 24 hours after exposure.

22 Apr 2021

Can SARS-CoV-2 host factor protein interactions help identify antiviral drug targets?

In a new study proteomic peptide-phage display is utilized to profile the novel SLiM-based interactions that mediate host factor interactions in 229 RNA viruses, with a special focus on SARS-CoV-2, to reveal mechanistic insights and identify drug targets.

22 Apr 2021

How effective is the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine? A real-world study in Sweden

Investigating a population in southern Sweden, a new study has found that a single dose of the vaccine is only about 42% effective in preventing coronavirus disease 2019 (COVID-19). But seven days after the second dose, the vaccine can prevent COVID-19 in 86% of the population.

22 Apr 2021

Researchers conduct a SARS-CoV-2 serosurvey of blood donors in New Zealand

New research has been released, which focuses on the transmission and prevalence of SARS-CoV-2 in New Zealand, through a blood donor serosurvey.

22 Apr 2021

Researchers aim to better understand clinical features associated with COVID-19 mortality

To better understand the COVID-19 clinical feaures associated with mortality, an interdisciplinary team of researchers has investigated important factors and their influence on a patient’s death.

22 Apr 2021

Study offers insights into protective effects of dietary supplements against COVID-19

Taking multivitamins, omega-3, probiotics or vitamin D supplements may lessen the risk of testing positive for SARS-CoV-2, the virus responsible for COVID-19 infection--at least among women--indicates a large population study, published online in the journal BMJ Nutrition Prevention & Health.

22 Apr 2021

Some COX inhibitors/NSAIDs increase COVID-19 severity

A startling new preprint research paper posted to the medRxiv server warns against the use of commonly used non-steroidal anti-inflammatory drugs (NSAIDs) belonging to the category of cyclooxygenase inhibitors (COX inhibitors) in patients with coronavirus disease 2019 (COVID-19).

22 Apr 2021

Cleaning frequency key to limiting SARS-CoV-2 spread at theme parks

A new preprint research paper provides some insights into how this may be done using computational modeling. The study, which appeared on the medRxiv server, deals with the mitigation strategies that must be implemented in order to contain the virus.

22 Apr 2021

Metabolic testing of COVID-19 patients through skin imprints

There is, therefore, a great need to understand how the illness can be diagnosed using more convenient and inexpensive methods. A new study posted to the medRxiv preprint server reveals the potential role of skin imprints to test for biomarkers that indicate a diagnosis of COVID-19 in a non-invasive way.

22 Apr 2021

B.1.1.7 variant 45% more infectious than wild-type SARS-CoV-2, but can be effectively contained by BNT162b2 vaccine

The SARS-CoV-2 B.1.1.7 variant, also called the UK variant, was identified in London as well as in Southeast and East of England in December 2020. Since its emergence, the UK variant has undergone several mutations that have been said to have altered its infectivity and transmissibility in the community. The B.1.1.7 variant is defined by 17 mutations, several of which are located in the SARS-CoV-2 spike protein that mediates viral attachment and entry into human cells.

21 Apr 2021

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Researchers in the United States have developed adenovirus vectors that may be more effective at generating immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than those used in the vaccines that are currently being rolled out to help combat the coronavirus disease 2019 (COVID-19) pandemic.

21 Apr 2021

Maintaining swimming pools in line with UK guidelines eliminates SARS-CoV-2 risk

Researchers in the UK have conducted a study showing that maintaining swimming pool water in accordance with UK guidelines is sufficient to eliminate the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) being transmitted between bathers.

21 Apr 2021

Argonne's Advanced Photon Source guided the development of new COVID-19 vaccine now in trials

Human clinical trials have begun on a new vaccine candidate that may protect against not only SARS-CoV-2, the virus that causes COVID-19, but against at least two of the variants emerging around the world.

21 Apr 2021

SARS-CoV-2 infection induces polyfunctional antibodies that can destroy infected cells

Drawing on epidemiological field studies and the FrenchCOVID hospital cohort coordinated by Inserm, teams from the Institut Pasteur, the CNRS and the Vaccine Research Institute (VRI, Inserm/University Paris-Est Créteil) studied the antibodies induced in individuals with asymptomatic or symptomatic SARS-CoV-2 infection.

21 Apr 2021

Researchers discover how SARS viruses enhance the production of viral proteins in infected cells

Coronavirus researchers led by Professor Rolf Hilgenfeld of the University of Luebeck and PD Dr. Albrecht von Brunn of the Ludwig-Maximilian Universitaet in Munich have discovered how SARS viruses enhance the production of viral proteins in infected cells, so that many new copies of the virus can be generated.

21 Apr 2021

Interfering RNA nanoparticles could be a potential COVID-19 therapy

Study shows lipid nanoparticle-based siRNA is potent in suppressing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of coronavirus disease 2019 (COVID-19) – in cells as well as in mice models.

21 Apr 2021

SARS-CoV-1 utilizes ORF3a protein to trigger viral release

Scientists in the USA – from the Johns Hopkins University and the University of Maryland – have recently uncovered the mechanism by which SARS-CoV-1 is released from the infected cells.

21 Apr 2021

SARS News and Research

Preclinical study from NIH/Moderna: Correlates of SARS-CoV-2 immunity in non-human primates

Slow COVID-19 vaccine rollout in Tokyo could mean no Olympic and Paralympic Games

New Phase 3 trial of therapeutics begins enrolling severely ill hospitalized COVID-19 patients

House flies can carry SARS-CoV-2 up to 24 hours after exposure, study finds

Can SARS-CoV-2 host factor protein interactions help identify antiviral drug targets?

How effective is the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine? A real-world study in Sweden

Researchers conduct a SARS-CoV-2 serosurvey of blood donors in New Zealand

Researchers aim to better understand clinical features associated with COVID-19 mortality

Study offers insights into protective effects of dietary supplements against COVID-19

Some COX inhibitors/NSAIDs increase COVID-19 severity

Cleaning frequency key to limiting SARS-CoV-2 spread at theme parks

Metabolic testing of COVID-19 patients through skin imprints

B.1.1.7 variant 45% more infectious than wild-type SARS-CoV-2, but can be effectively contained by BNT162b2 vaccine

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Maintaining swimming pools in line with UK guidelines eliminates SARS-CoV-2 risk

Argonne's Advanced Photon Source guided the development of new COVID-19 vaccine now in trials

SARS-CoV-2 infection induces polyfunctional antibodies that can destroy infected cells

Researchers discover how SARS viruses enhance the production of viral proteins in infected cells

Interfering RNA nanoparticles could be a potential COVID-19 therapy

SARS-CoV-1 utilizes ORF3a protein to trigger viral release

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News